Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Nov 8, 2013)
  • 8-K (Oct 29, 2013)
  • 8-K (Oct 22, 2013)
  • 8-K (Oct 2, 2013)
  • 8-K (Sep 27, 2013)
  • 8-K (Sep 11, 2013)

 
Other

Allergan Finance LLC 8-K 2007

Documents found in this filing:

  1. 8-K
  2. 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant To Section 13 or 15(d) Of the Securities and Exchange Act Of 1934

 

 

 

June 26, 2007
Date of Report (Date of earliest event reported)

 

 

 

WATSON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

001-13305

 

95-3872914

(State or other Jurisdiction
of Incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification Number)

 

 

 

 

 

311 Bonnie Circle

 

 

 

92880

Corona, California

 

 

 

(Zip Code)

(Address of principal executive offices)

 

 

 

 

 

(951) 493-5300

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 




Item 5.02                                             Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

2007 Senior Executive Equity Compensation Program.

On June 26, 2007, the Compensation Committee of the Board of Directors of Watson Pharmaceuticals, Inc., (the “Company”) adopted the 2007 Senior Executive Equity Compensation Program (the “Program”).  The terms of the Program are not contained in a formal written plan.

Pursuant to the Program, each senior executive (other than the Chief Executive Officer) of the Company (each, an “Executive Officer”) is eligible to receive a restricted stock award.  Depending on the Executive Officer’s position with the Company, target awards range between 700 and 15,000 restricted shares of Company common stock (the “Target Award”).  An individual who becomes an Executive Officer of the Company after the beginning of the fiscal year will be eligible for a prorated Target Award, based upon the portion of time in 2007 during which the individual serves as an Executive Officer of the Company.

The number of restricted shares granted to an Executive Officer will be based on the Company achieving certain earnings before interest, taxes, depreciation and amortization targets, adjusted for non-cash charges, share-based compensation, acquisition related charges, restructuring charges, litigation charges, gains or losses on debt repurchase, and gains or losses on sales of operating assets or securities (as adjusted, the “Financial Targets”) during 2007.  The actual award of restricted stock to an Executive Officer can range from 0% to 150% of such Executive Officer’s Target Award, based upon the level of achievement of such Financial Targets.

Restricted stock awards awarded under the Program, if any, will be issued after the end of 2007, and will vest 50% on the second anniversary of such restricted stock award, and 50% on the fourth anniversary of such restricted stock award.  The Compensation Committee will determine whether and to what extent restricted stock awards will be awarded for fiscal year 2007 after the end of 2007.

2




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Dated: June 29, 2007

 

 

WATSON PHARMACEUTICALS, INC.

 

 

 

 

 

 

 

 

 

 

 

By:

/s/ David A. Buchen

 

 

 

 

David A. Buchen

 

 

 

 

Senior Vice President, General Counsel and Secretary

 

 

3



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki